We are excited to rapidly advance CX-2051 for the benefit of CRC patients and to explore the full potential of this novel ADC.” CX-2051 Phase 1a Interim Data Summary in Advanced, Late-line Colorectal ...

We are excited to rapidly advance CX-2051 for the benefit of CRC patients and to explore the full potential of this novel ADC.” CX-2051 Phase 1a Interim Data Summary in Advanced, Late-line ...

today announced positive interim Phase 1 data for its EpCAM PROBODY ® ADC candidate, CX-2051, in advanced, late-line CRC. The data are as of an April 7 th 2025 data cutoff from the ongoing CTMX ...

Colorectal cancer (CRC) is a significant global health burden ... collaboration conducted a prospective preplanned pooled analysis of six randomized phase III trials, comparing 3 versus 6 months of ...

Rgenta's Phase 1a/b clinical trial of RGT-61159 is a multi-center, open-label study dose escalation and expansion study in patients with advanced relapsed or refractory ACC or CRC. The Phase 1a/b ...

The Phase 1/2 trial (NCT05731947) is designed to assess the safety, tolerability, and anti-tumor activity of revumenib in patients with relapsed or refractory metastatic MSS CRC. The Phase 1a dose ...

Petosemtamab is a Biclonics® targeting EGFR and LGR5. The phase 2, open-label trial will evaluate the safety and preliminary antitumor of petosemtamab and a regimen of chemotherapy (FOLFIRI or ...

California Resources Corporation CRC has concluded its $1.13 billion all-stock merger, announced in February 2024, with Aera Energy, LLC. The total valuation of the deal is $2.1 billion ...

Multitarget stool-based tests are showing promise for colorectal cancer (CRC) screening in average-risk individuals and could edge out the current standard fecal immunochemical test (FIT).

Despite their potential, however, the magnetic phase diagram of these materials remains largely unexplored. To uncover more, a team of researchers, led by Professor Ryuji Tamura from the ...

The feedback we received from our associates throughout the first phase of our CRC screening campaign was entirely positive. Mainz Biomed made it easy for us to implement the test in our BGM ...